Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellsubjectsbrainmetastasesdisease
  Phrases that lowered it: trialhas historyrangeaminotransferasemk
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 16.1% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 86 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports before start: 360912 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 335 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 78.7% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 72853 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases NCT03498612 · started 2018 · scored riskier than 65% of active trials terminated
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma NCT03401853 · started 2018 · scored riskier than 54% of active trials terminated
• Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT03210662 · started 2018 · scored riskier than 93% of active trials completed
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL NCT03305445 · started 2018 · scored riskier than 84% of active trials completed
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04387227 · started 2021 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.